TCGA-FD-A6TH-01A-11R-A32O-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.303547963
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.470
- MITOTIC_SPINDLE+0.470
- MYC_TARGETS_V1+0.460
- UNFOLDED_PROTEIN_RESPONSE+0.410
- MYC_TARGETS_V2+0.400
- MTORC1_SIGNALING+0.390
- GLYCOLYSIS+0.370
- HEDGEHOG_SIGNALING+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
Top 10 suppressed
- KRAS_SIGNALING_DN-0.200
- PANCREAS_BETA_CELLS-0.200
- KRAS_SIGNALING_UP-0.190
- INFLAMMATORY_RESPONSE-0.110
- APICAL_SURFACE-0.060
- ALLOGRAFT_REJECTION-0.050
- XENOBIOTIC_METABOLISM-0.030
- NOTCH_SIGNALING-0.020
- BILE_ACID_METABOLISM+0.010
- P53_PATHWAY+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG544 | — | — | 0.868 |
| 2 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.863 |
| 3 | MNG252 | — | — | 0.859 |
| 4 | 5B474B14-FB1C-4B54-A9E8-3D652ADE6BA4 | — | — | 0.859 |
| 5 | SRR13311157 | — | — | 0.858 |
| 6 | SRR12696773 | — | — | 0.844 |
| 7 | SRR934967 | — | — | 0.844 |
| 8 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.837 |
| 9 | TCGA-E9-A1N6-01A-11R-A144-07 | — | C | 0.832 |
| 10 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |